Allogene Therapeutics
Sara Charmsaz is a seasoned professional in the field of Translational Sciences with a strong focus on oncology and biomarker discovery. Currently serving as Director of Translational Sciences at Allogene Therapeutics since July 2024, Sara previously held positions as Associate Director and Senior Scientist at Sonoma Biotherapeutics from July 2021 to July 2024. Prior to this, Sara was a Principal Investigator and Senior Scientist at the Royal College of Surgeons in Ireland, where research centered on using multi-omic data for breast cancer biomarker identification. Additional experience includes significant roles at Pfizer/RCSI SFI Project, RCSI, and QIMR Berghofer Medical Research Institute, contributing to innovative research on breast cancer, leukemia, and glioblastoma. Sara earned a Ph.D. in Oncology and Cancer Biology from The University of Queensland, complemented by degrees in Biotechnology from Griffith University.
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.